Biological agents in head and neck cancer

Paolo Bossi, Laura D. Locati, Lisa Licitra

Research output: Contribution to journalArticlepeer-review


Survival of head and neck cancer (HNC) patients has not dramatically improved over the last 30 years, despite the advances in surgical techniques, chemotherapeutic agents and radiotherapy treatment planning and definition. Different studies in molecular biology of HNC have been carried out, providing useful results for clinical application. HNC usually includes malignant tumors arising from mucosa of the upper aerodigestive tract, from nasopharynx to larynx/trachea, while salivary gland and thyroid cancers are less frequently listed in this classification. In this review, we chose to provide a comprehensive review of the role of biological agents in head and neck subsites. Molecular characteristics and treatment-relevant signaling pathways will be briefly discussed along with the results of the more recent clinical studies that include biological agents.

Original languageEnglish
Pages (from-to)1643-1650
Number of pages8
JournalExpert Review of Anticancer Therapy
Issue number11
Publication statusPublished - Nov 2007


  • Biological agents
  • Clinical trials
  • Head and neck cancer
  • Molecular basis

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology


Dive into the research topics of 'Biological agents in head and neck cancer'. Together they form a unique fingerprint.

Cite this